Investors Urged to Explore Class Action Against Altimmune, Inc.

Author: Caleb Price Updated: 09-22-2025 08:26 AM

Class Action Lawsuit Announcement for Altimmune, Inc.

Berger Montague PC, a prominent national plaintiffs' law firm, is leading a class action lawsuit concerning Altimmune, Inc. (NASDAQ: ALT). The lawsuit targets investors who bought or acquired publicly traded securities of Altimmune during the designated class period. This period spans from the 10th of August to the 25th of June, 2025.

Important Deadline for Investors

For those who purchased Altimmune securities during the specified period, the firm advises acting promptly. Investors have until October 6, 2025, to apply for a role as a lead plaintiff representative in this class action. Understanding your legal rights is crucial at this stage, and interested parties should take this opportunity seriously.

Understanding Altimmune's Recent Trials

Altimmune is a clinical-stage biopharmaceutical company, focused on creating treatments for serious health issues like obesity and liver diseases, including MASH (metabolic dysfunction-associated steatohepatitis). In June 2025, Altimmune disclosed the results of its Phase 2b IMPACT trial of Pemvidutide aimed at treating MASH. Despite earlier optimistic statements from management, the trial did not achieve its primary endpoint of statistical significance in fibrosis reduction.

Impact on Stock Price

The announcement resulted in a dramatic decrease in Altimmune's stock price, plummeting 53.2% in a single trading session, falling from a close of $7.71 to $3.61 on that day. This sharp decline raised concerns among shareholders, leading to the current class action lawsuit.

Investor Resources and Contact Information

If you are an investor in Altimmune and need further details regarding this class action, it is advisable to reach out for more information. You can contact the legal team at Berger Montague directly to discuss your rights and potential options.

About Berger Montague

Berger Montague has been a significant name in securities class action litigation since its establishment in 1970. With a firm commitment to serving individual and institutional investors alike, the law firm has successfully represented clients in courts across the United States for over fifty years.

Frequently Asked Questions

What is the class action lawsuit regarding?

The class action lawsuit concerns Altimmune, Inc. and is about securities fraud that may have affected investors who held shares during the specified period.

Who can join the class action?

Investors who purchased or acquired Altimmune securities from August 10, 2023, through June 25, 2025, are eligible to seek lead plaintiff representation.

What happened with Altimmune’s stock?

The stock experienced a significant decline of 53.2% following the release of trial results from the company's Phase 2b investigation into Pemvidutide.

What should investors do now?

Investors should consider reaching out to Berger Montague for details on their rights and the potential implications of the class action.

How can investors contact Berger Montague?

Interested parties can contact Andrew Abramowitz at (215) 875-3015 or Caitlin Adorni at (267) 764-4865 for inquiries related to the class action.

About The Author

Hey there I'm Caleb Price, a writer and financial specialist who loves to assist others in understanding the financial world. Having years of practical experience and a solid background in finance, my area of expertise is converting difficult financial ideas into useful, doable insights for my blog and publications. My goal with my writing is to give readers the information and assurance they need to successfully negotiate their financial journeys.

My ability to interact with a wide range of people—from novices starting their investing journey to seasoned investors looking for new approaches—has come from contributing to several financial blogs. Making money approachable and understandable is my goal; this will enable you to make wise choices and realize your financial objectives. We appreciate you coming along on this path to success and financial empowerment on Investors Hangout.

Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.